Leukaemia clinical trials

Explore recruiting leukaemia clinical trials.

Recruiting leukaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Leukaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression

Germany, Italy, Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, multicenter, open-label, prospective, non-randomized study to evaluate the safety and efficacy of ARI0002h, a CAR-T cell against BCMA, for the initial treatment of patients with primary plasma cell leukaemia

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)

Norway, Denmark, Netherlands, Lithuania, Finland, Germany +8 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Multicentre, Open-Label, Randomized, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) with Chronic Lymphocytic Leukemia and Moderate to Severe Cardiac Impairment

Spain, Italy, Poland, Czechia

Therapeutic use (Phase IV) EU CTIS Study details

Leukaemia trials by city

Leukaemia in Toronto Leukaemia in Vancouver Leukaemia in Montreal Leukaemia in Calgary Leukaemia in Edmonton Leukaemia in Ottawa Leukaemia in Winnipeg Leukaemia in Quebec City Leukaemia in Hamilton Leukaemia in Kitchener Leukaemia in London Leukaemia in Halifax Leukaemia in New York Leukaemia in Los Angeles Leukaemia in Chicago Leukaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease